PL1838301T3 - Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe - Google Patents
Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bóloweInfo
- Publication number
- PL1838301T3 PL1838301T3 PL04802396T PL04802396T PL1838301T3 PL 1838301 T3 PL1838301 T3 PL 1838301T3 PL 04802396 T PL04802396 T PL 04802396T PL 04802396 T PL04802396 T PL 04802396T PL 1838301 T3 PL1838301 T3 PL 1838301T3
- Authority
- PL
- Poland
- Prior art keywords
- resiniferatoxin
- rtx
- pain
- agent
- preparation
- Prior art date
Links
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CH2004/000756 WO2006069451A1 (de) | 2004-12-28 | 2004-12-28 | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
| EP04802396.4A EP1838301B1 (de) | 2004-12-28 | 2004-12-28 | Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1838301T3 true PL1838301T3 (pl) | 2015-08-31 |
Family
ID=34959549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04802396T PL1838301T3 (pl) | 2004-12-28 | 2004-12-28 | Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20080139641A1 (pl) |
| EP (1) | EP1838301B1 (pl) |
| JP (1) | JP5775246B2 (pl) |
| CA (1) | CA2594202C (pl) |
| DK (1) | DK1838301T3 (pl) |
| ES (1) | ES2533256T3 (pl) |
| PL (1) | PL1838301T3 (pl) |
| WO (1) | WO2006069451A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063842A2 (en) | 2006-11-02 | 2008-05-29 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
| US8697155B2 (en) * | 2008-07-22 | 2014-04-15 | Mayo Foundation For Medical Education And Research | Treatment of obesity and related disorders |
| US8870876B2 (en) | 2009-02-13 | 2014-10-28 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8277459B2 (en) | 2009-09-25 | 2012-10-02 | Tarsus Medical Inc. | Methods and devices for treating a structural bone and joint deformity |
| US8652141B2 (en) | 2010-01-21 | 2014-02-18 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| US8696719B2 (en) | 2010-06-03 | 2014-04-15 | Tarsus Medical Inc. | Methods and devices for treating hallux valgus |
| WO2012168450A1 (en) | 2011-06-10 | 2012-12-13 | Queen Mary & Westfield College | Artemisinin and its derivatives for use in the treatment of trauma haemorrhage and associated conditions |
| WO2014019095A1 (de) * | 2012-08-03 | 2014-02-06 | Mestex Ag | Resiniferatoxin-lösung |
| US9603831B2 (en) | 2012-12-12 | 2017-03-28 | Queen Mary & Westfield College, University Of London | Artemisinin and its derivatives for use in the treatment of kidney disease |
| US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
| CN110035740B (zh) | 2016-11-02 | 2023-08-04 | 中枢疗法公司 | 稳定的水性辣椒素可注射制剂及其医学用途 |
| US11400136B2 (en) * | 2017-06-19 | 2022-08-02 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
| MX2020000488A (es) | 2017-07-20 | 2020-10-28 | Centrexion Therapeutics Corp | Metodos y composiciones para el tratamiento del dolor usando capsaicina. |
| MX2020002692A (es) * | 2017-09-11 | 2020-10-14 | Sorrento Therapeutics Inc | Formulacion de resiniferatoxina. |
| CN113490745A (zh) * | 2018-12-21 | 2021-10-08 | 索伦托药业有限公司 | 神经周施用树脂毒素治疗适应不良性疼痛 |
| US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
| MX2021008716A (es) * | 2019-01-22 | 2021-08-24 | Sorrento Therapeutics Inc | Metodo para tratar dolor de osteoartritis al administrar resiniferatoxina. |
| CN110123833A (zh) * | 2019-05-31 | 2019-08-16 | 龚啸元 | 一种关节镜手术用灌流液及其制备方法 |
| IL297063A (en) * | 2020-04-15 | 2022-12-01 | Gruenenthal Chemie | Resiniparatoxin preparations |
| US20250228815A1 (en) | 2024-01-15 | 2025-07-17 | Gruenenthal Gmbh | Lyophilized resiniferatoxin |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3104085A (en) | 1960-07-18 | 1963-09-17 | Ind Paper Log Inc | Compressed fibrous articles |
| US4939149A (en) | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
| US4997853A (en) * | 1988-12-02 | 1991-03-05 | Galenpharma, Inc. | Method and compositions utilizing capsaicin as an external analgesic |
| AU5744490A (en) * | 1989-05-15 | 1990-12-18 | Afferon Corporation | Composition and method for neural desensitization |
| DK0998288T4 (da) | 1997-03-13 | 2005-08-22 | James N Campbell | Sammensætninger indeholdende kapasaicin eller kapsaicinanaloge og et lokalbedövelsesmiddel |
| GB9711962D0 (en) | 1997-06-10 | 1997-08-06 | Reckitt & Colmann Prod Ltd | Therapeutically active compositions |
| CA2425961A1 (en) * | 2000-10-16 | 2002-04-25 | Ortho-Mcneil Pharmaceutical, Inc. | Improved ligand binding assays for vanilloid receptors |
| WO2002058688A1 (de) * | 2001-01-24 | 2002-08-01 | Mestex Ag | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen |
| CA2442049C (en) | 2001-03-22 | 2010-06-01 | Michael J. Iadarola | Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist |
| US20030104085A1 (en) * | 2001-12-05 | 2003-06-05 | Yeomans David C. | Methods and compositions for treating back pain |
| ES2562025T3 (es) | 2002-12-18 | 2016-03-02 | Centrexion Therapeutics Corporation | Administración de capsaicinoides para el tratamiento de la artrosis |
| JP2008524267A (ja) * | 2004-12-22 | 2008-07-10 | メステックス アクチェンゲゼルシャフト | バニロイド受容体作用薬と神経再生物質阻害物質との混合物、鎮痛薬を生成するためのそれらの使用、および該鎮痛薬を適用する方法 |
-
2004
- 2004-12-28 PL PL04802396T patent/PL1838301T3/pl unknown
- 2004-12-28 ES ES04802396.4T patent/ES2533256T3/es not_active Expired - Lifetime
- 2004-12-28 CA CA 2594202 patent/CA2594202C/en not_active Expired - Lifetime
- 2004-12-28 JP JP2007548653A patent/JP5775246B2/ja not_active Expired - Lifetime
- 2004-12-28 WO PCT/CH2004/000756 patent/WO2006069451A1/de not_active Ceased
- 2004-12-28 DK DK04802396.4T patent/DK1838301T3/en active
- 2004-12-28 EP EP04802396.4A patent/EP1838301B1/de not_active Expired - Lifetime
- 2004-12-28 US US11/722,779 patent/US20080139641A1/en not_active Abandoned
-
2010
- 2010-04-07 US US12/755,994 patent/US9044452B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2594202C (en) | 2013-12-03 |
| US20080139641A1 (en) | 2008-06-12 |
| JP2008525504A (ja) | 2008-07-17 |
| DK1838301T3 (en) | 2015-04-27 |
| WO2006069451A1 (de) | 2006-07-06 |
| ES2533256T3 (es) | 2015-04-08 |
| US20100196281A1 (en) | 2010-08-05 |
| EP1838301B1 (de) | 2015-01-28 |
| JP5775246B2 (ja) | 2015-09-09 |
| CA2594202A1 (en) | 2006-07-06 |
| US9044452B2 (en) | 2015-06-02 |
| EP1838301A1 (de) | 2007-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1838301T3 (pl) | Użycie resiniferatotoksyny (RTX) dla wytwarzania środka leczącego stany bólowe | |
| IL169104A0 (en) | Apparatus for the manufacture of medical devices | |
| GB0522311D0 (en) | Pharmaceutical compositions for the treatment of pain | |
| AP2007004157A0 (en) | N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain | |
| EP1809265A4 (en) | METHOD FOR THE TREATMENT OF SYNNUCLEOPATHIES | |
| IL213897A0 (en) | Ultrasound contrast agent dosage formulation | |
| IL177232A0 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| EP1626692A4 (en) | COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS | |
| IL187405A0 (en) | Methods and compositions for the treatment of pain | |
| IL178827A0 (en) | Use of reboxetine for the treatment of pain | |
| IL183893A0 (en) | Pharmaceutical compositions for the treatment of cellulite | |
| IL169171A0 (en) | Manufacturing apparatus for the packaging of medical devices including integrated lancets | |
| PL1740204T3 (pl) | Lecznicze zastosowanie alfa-mannozydazy | |
| IL179337A0 (en) | Pharmaceutical compositions for the treatment of pruritus | |
| EP1867640A4 (en) | MEANS FOR TREATING SOLID TUMORS | |
| EP1750698A4 (en) | 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | |
| IL178907A0 (en) | Use of sulglicotide for the treatment of mucositis | |
| IL172101A0 (en) | Use of indazole derivatives for the treatment of neuropathic pain | |
| IL170706A0 (en) | Use of atii antagonist for the treatment or prevention of metabolic syndrome | |
| ZA200710476B (en) | Methods and compositions for the treatment of pain | |
| EP1900363A4 (en) | THERAPEUTIC AGENT AGAINST PAIN | |
| GB0412262D0 (en) | Use of compounds for the treatment of pain | |
| ZA200608015B (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| ZA200704859B (en) | Pharmaceutical compositions for the treatment of cellulite | |
| LT1740204T (lt) | Medicininis alfa-manozidazės panaudojimas |